A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Interventional
Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Red Blood Cell Mass
Up to One Year
Yes
Abderrahmane Laadem, MD
Study Director
Celgene Corporation
United States: Food and Drug Administration
ACE-011-ST-001
NCT01190644
June 2010
August 2013
Name | Location |
---|---|
Weinberg Cancer Institution at Franklin Square | Baltimore, Maryland 21237 |
Saint Agnes Healthcare | Baltimore, Maryland 21229 |
Pennsylvania Oncology | Philadelphia, Pennsylvania 19106 |